Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
States can decide whether to cover obesity drugs under Medicaid
Front Oncol (2018) 8:367
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
FDA safety-risk list
Acta 1850 , 15271542, (2025)
Clinically, BPC-157 and TB-500 are synergistic
US$ 24.34
US$ 27.05
US$ 20.25
US$ 25.28
US$ 20.23
US$ 24.61
US$ 29.16
US$ 21.72
US$ 22.58
